Board meeting on Nov 3 to consider Q2 and H1 FY26 results

Results View source PDF Explain this filing

NEPHROPLUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹617.20

prior close

₹608.10

announcement price

After-mkt

timing

Nifty Microcap 250market+0.2%-1.1% vs market

Healthcare Service Provider peers, median of 26sector-0.4%-0.5% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 0.5 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-1.0

15m

-0.7

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9+0.2-1.1-0.4-0.5

Next day

-0.1+0.9-1.0+0.2-0.4

-1.0-0.8-0.2-0.2-0.8

-0.2-0.1-0.1-0.3+0.1

-1.8-1.7-0.1-1.5-0.3

-2.0-4.3+2.3-3.1+1.1

-4.4-7.5+3.1-3.2-1.2

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Nephrocare Health Services has informed BSE and NSE that its Board of Directors will meet on November 3, 2026, to consider and approve the Un-audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. The trading window for designated persons and their immediate relatives is closed from October 1 to November 5, 2026.

Likely market impact

Routine board meeting intimation ahead of Q2 results. Investors should await the actual results on Nov 3 for key numbers.